Clinical trials: Colorectal Cancer Metastatic
Colorectal Cancer, Squamous Cell Head and Neck Cancer
A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers
The purpose of this study was to evaluate the safety and tolerability of escalating doses of the MM-121 plus cetuximab and the MM-121 plus cetuximab plus irinotecan combination.
- Conditions
- Colorectal Cancer, Squamous Cell Head and Neck Cancer, Non-small Cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT01451632
- Testing
- MM-121, Irinotecan, Cetuximab
- Where
- 4 sites in United States
- Volunteers
- 48 people
- Sponsor
- Merrimack Pharmaceuticals
Colorectal Liver Metastases, Quality of Life
Quality of Life and Liver Metastases
An increasing aggressiveness in the surgical approach of colorectal liver metastases is observed. This seems only justified when, besides prolongation of survival, also the health status of patients is considered.
- Trial name
- NCT00184834
- Testing
- quality of life
- Where
- Netherlands
- Volunteers
- 100 people
- Sponsor
- Radboud University Medical Center
Metastatic Colorectal Cancer (mCRC)
Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients
This is a multicenter, open label, randomized bioequivalence study of BEVZ92 (bevacizumab biosimilar) and Avastin® with 2 parallel arms to compare the pharmacokinetic (PK) profile of BEVZ92 and Avastin® in combination with FOLFOX…
- Trial name
- NCT02069704
- Testing
- Bevacizumab biosimilar (BEVZ92), Avastin® (bevacizumab, reference product)
- Where
- 18 sites in Argentina, Brazil and 3 more
- Volunteers
- 142 people
- Sponsor
- mAbxience Research S.L.
Colorectal Cancer Metastatic
A Real-world Study of Chidamide in Combination with PD-1/PD-L1 Antibodies and Anti-angiogenic Agents in Advanced MSS Colorectal Cancer
This is an observational , multicenter, real-world study aimed at evaluating the efficacy and safety of the combination of immune checkpoint inhibitors, chidamide and antiangiogenic agents in Microsatellite Stable advanced…
- Trial name
- NCT06682247
- Testing
- Chidamide, Tucidinostat; PD-1/PD-L1 inhibitor or double antibodies; Bevacizumab or tyrosine kinase inhibitors
- Volunteers
- 200 people
- Sponsor
- Feng Wang
Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic
A Phase I Study to Evaluate the Safety and Efficacy of L19IL2 in Combination With Ruxolitinib in Patients With Advanced Solid Tumors
This trial aims to address unmet medical needs in advanced solid tumors, specifically metastatic clear cell renal carcinoma, locally advanced or metastatic pancreatic adenocarcinoma, and metastatic colorectal adenocarcinoma.
- Conditions
- Renal Carcinoma Metastatic, Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Metastatic Colorectal Carcinoma (mCRC)
- Trial name
- NCT07566897
- Testing
- L19IL2, Ruxolitinib
- Where
- Italy
- Volunteers
- 96 people
- Sponsor
- Philogen S.p.A.
Carcinoma, Hepatocellular, Metastatic Colorectal Cancer
Vandetanib-eluting Radiopaque Embolic Beads in Patients With Resectable Liver Malignancies
This is a pilot, open label single arm phase 0 window of opportunity study of vandetanib-eluting radiopaque beads in patients with resectable liver malignancies.
- Trial name
- VEROnA (NCT03291379)
- Testing
- BTG-002814
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Boston Scientific Corporation
Colorectal Cancer, RAS Mutation
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
This study is designed to explore the efficacy and safety of anti-PD-1 antibody plus bevacizumab and chemotherapy as first-line treatment for patients with RAS-mutant, microsatellite stable, metastatic colorectal cancer.
- Conditions
- Colorectal Cancer, RAS Mutation, Colorectal Neoplasms, Microsatellite Stable Colorectal Carcinoma
- Trial name
- NCT06206096
- Testing
- oxaliplatin+capecitabine+bevacizumab+PD-1 antibody
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Chinese PLA General Hospital
Early-onset Colorectal Cancer, Late-onset Colorectal Cancer
Distinct Metastatic Phenotypes Between Early-onset and Late-onset Colorectal Cancer
The clinical and pathological features of early-onset colorectal cancer (EOCRC) differ from those of late-onset colorectal cancer (LOCRC).
- Trial name
- NCT06040021
- Testing
- standardized treatment
- Volunteers
- 15,244 people
- Sponsor
- Fudan University
Colorectal Cancer
Study of the Safety and Effectiveness of HIFU Combined With REGOTORI for Metastatic Colorectal Cancer
This study intends to perform high-intensity focused ultrasound combined with REGOTORI in patients with multiline drug-resistant metastatic colorectal cancer to explore the safety and efficacy of patients.
- Trial name
- NCT04819516
- Testing
- high-intensity focused ultrasound therapy, Toripalimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis
Modified Short-Course Radiotherapy Combined With Immunochemotherapy and Targeted Therapy as First-Line Treatment for MSS Metastatic Colorectal Cancer
This is a single-arm interventional study targeting patients with initially unresectable MSS-type advanced colorectal cancer with liver and/or lung and peritoneal metastasis.
- Trial name
- NCT07512674
- Testing
- Receiving lymph node-sparing modified short-course radiotherapy combined with tislelizumab, CAPOX chemotherapy and bevacizumab targeted therapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Sir Run Run Shaw Hospital
Metastatic Colorectal Cancer
TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC
Primary Objective: To determine disease control rate (DCR) of TS-1® in patients with heavily pre-treated metastatic colorectal cancer Secondary Objectives: To determine objective response rate (ORR) To determine time to…
- Trial name
- NCT03517618
- Testing
- S-1+leucovorin
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- TTY Biopharm
Secondary Malignant Neoplasm of Liver, Colorectal Neoplasms
Oslo Randomized Laparoscopic Versus Open Liver Resection for Colorectal Metastases Study
The purpose of the study is to compare outcomes of laparoscopic versus open liver resection for colorectal metastases in a prospective and randomized study.
- Trial name
- Oslo-CoMet (NCT01516710)
- Testing
- Open liver resection, Laparoscopic liver resection
- Where
- Norway
- Volunteers
- 280 people
- Sponsor
- Oslo University Hospital
Colorectal Cancer Stage IV
Combination With Sintilimab and XELOX+Bevacizumab as 1st Line Therapy in RAS-mutant Metastatic Colorectal Cancer
Sintilimab (R\&D code: IBI308) is a recombinant human-derived IgG4 type PD-1 monoclonal antibody. PD-1 inhibitor combined with chemotherapy has synergistic effect to further enhance anti-tumor immunity.
- Trial name
- NCT05171660
- Testing
- Sintilimab, Bevacizumab, Oxaliplatin
- Where
- China
- Volunteers
- 446 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Colorectal Carcinoma, Neoplasm Metastasis
CIRSE Registry for LifePearl Microspheres
The application of transarterial chemoembolisation (TACE) using LifePearl Microspheres loaded with Irinotecan in liver-only or liver-dominant metastatic disease in patients with colorectal adenocarcinoma will be observed.
- Trial name
- CIREL (NCT03086096)
- Testing
- LifePearl Microspheres loaded with Irinotecan
- Where
- Austria
- Volunteers
- 152 people
- Sponsor
- Cardiovascular and Interventional Radiological Society of Europe
Colorectal Cancer, Liver Neoplasms
HAI Via Interventionally Implanted Port Catheter Systems
Procedures to provide interventional implantation of a port catheter system into the hepatic artery and adjacent regional chemotherapy of the liver are optimized in the scope of an open, single-arm trial in patients with…
- Conditions
- Colorectal Cancer, Liver Neoplasms, Hepatocellular Carcinoma, Gallbladder Cancer
- Trial name
- NCT00356161
- Testing
- interventionally implanted hepatic arterial port catheter
- Where
- 2 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Charite University, Berlin, Germany
Metastatic Colorectal Cancer, Triple Negative Breast Cancer
Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors
To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.
- Conditions
- Metastatic Colorectal Cancer, Triple Negative Breast Cancer, Prostate Adenocarcinoma, Stomach Adenocarcinoma
- Trial name
- MATILDA (NCT03982173)
- Testing
- Tremelimumab, Durvalumab
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Metastatic Colorectal Cancer
Sacituzumab Govitecan in Metastatic Colorectal Cancer
This is a Phase: II/III, open-label, multicenter (at least four centers in Germany) study of Sacituzumab Govitecan (SG) in metastatic colorectal cancer patients who are refractory to at least two lines of standard of care…
- Trial name
- TROPHIT1 (NCT06243393)
- Testing
- Sacituzumab Govitecan (SG), Physicians Choice (PhC).
- Where
- Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital Heidelberg
Metastatic Colorectal Cancer, mCRC
Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer
This is an open-label phase II study, with the aim of investigating the efficacy and safety of Tislelizumab + Fruquintinib combination therapy in ARID1A-mutated pMMR/MSS metastatic colorectal cancer who have been treated with…
- Trial name
- NCT05690035
- Testing
- Tislelizumab & Fruquintinib
- Where
- 2 sites in China
- Sponsor
- Sun Yat-sen University
ColoRectal Cancer, Liver Metastasis Colon Cancer
COLLISION Trial - Colorectal Liver Metastases: Surgery vs Thermal Ablation
The primary objective is to prove non-inferiority of thermal ablation compared to hepatic resection in patients with at least one resectable and ablatable colorectal liver metastases (≤3cm) and no extrahepatic disease.
- Conditions
- ColoRectal Cancer, Liver Metastasis Colon Cancer, Liver Metastases, Surgery
- Trial name
- COLLISION (NCT03088150)
- Testing
- Thermal ablation, Surgical resection
- Where
- Netherlands
- Volunteers
- 618 people
- Sponsor
- Amsterdam UMC, location VUmc